Worth Venture Partners’s Mereo BioPharma MREO Stock Holding History

Worth Venture Partners’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-76,513	Closed	-$54.1K	–	182
2023 Q1	$54.1K	Buy	+76,513	New	+$68.9K	0.03%	156

Other funds holding MREO

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Alkeon Capital Management

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Worth Venture Partners's MREO Position: Q2 2023 in Review

Worth Venture Partners sold out of Mereo BioPharma (MREO) in Q2 2023, closing a stake of 76,513 shares — an estimated $54.1K sold.

Worth Venture Partners first reported a position in MREO in Q1 2023 and held it in 1 quarter. The position peaked at $54.1K in Q1 2023. 53 funds tracked by Wall St. Rank hold MREO as of Q2 2023.

Worth Venture Partners reported no remaining Mereo BioPharma position as of Q2 2023 after selling out during the quarter.
Worth Venture Partners sold 76,513 Mereo BioPharma shares in Q2 2023, an estimated $54.1K.
Worth Venture Partners first reported a position in Mereo BioPharma in Q1 2023 and held it in 1 quarter.
Worth Venture Partners's Mereo BioPharma position peaked at $54.1K in Q1 2023.
53 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2023.

Based on Worth Venture Partners's 13F filing for Q2 2023, filed 14 Aug 2023.